Evidence map›Paper›PMID 28226398›Full record

ArticleAllergy2017

Dysregulation of interleukin 5 expression in familial eosinophilia.

S Prakash Babu, Y-Y K Chen, S Bonne-Annee, J Yang, I Maric, T G Myers, T B Nutman, A D Klion

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00091871 (A Longitudinal Study of Familial Hypereosinophilia), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00091871 recruitingnot on this map

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

TypeobservationalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2005Enrolled50ConditionsEosinophilia, Hypereosinophilic Syndrome
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Approach to Patients with Eosinophilia.The Medical clinics of North America · 2020
    Review
  8. Review
  9. Review
  10. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.The journal of allergy and clinical immunology. In practice
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

S Prakash BabuLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Y-Y K ChenLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
S Bonne-AnneeLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
J YangLaboratory of Human Retrovirology and Immunoinformatics, Applied and Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
I MaricDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
T G MyersGenomic Technologies Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
T B NutmanLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
A D KlionLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4986-5326
National Institutes of Health · USLeidos (United States) · USNational Institutes of Health Clinical Center · US

Funding

Infectious Diseases Research Technologies Core - BethesdaZICAI001051 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$226.1M
Eosinophils and Eosinophil Activation in the Pathogenesis of Human DiseaseZIAAI001130 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KLION, AMY · 2010 to 2025
$22.5M
Laboratory Assessment of Patients with Hypereosinophilic SyndromeZIACL080004 · CLC · CLINICAL CENTER · PI MARIC, IRINA · 2009 to 2025
$0k
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 AI999999NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

backgroundFamilial eosinophilia (FE) is a rare autosomal dominant inherited disorder characterized by the presence of lifelong peripheral eosinophilia (>1500/μL). Mapped to chromosome 5q31-q33, the genetic cause of FE is unknown, and prior studies have failed to demonstrate a primary abnormality in the eosinophil lineage.

objectiveThe aim of this study was to identify the cells driving the eosinophilia in FE.

methodsMicroarray analysis and real-time PCR were used to examine transcriptional differences in peripheral blood mononuclear cells (PBMC), and in purified cell subsets from affected and unaffected family members belonging to a single large kindred. Cytokine levels in serum and PBMC culture supernatants were assessed by suspension array multiplexed immunoassays.

resultsWhereas IL-5 mRNA expression was significantly increased in freshly isolated PBMC from affected family members, this was not accompanied by increased mRNA expression of other Th2 cytokines (IL-4 or IL-13). Serum levels of IL-5 and IL-5 receptor α, but not IgE, were similarly increased in affected family members. Of note, IL-5 mRNA expression was significantly increased in purified CD3+ CD4+, CD14+, CD19+, and ILC2 cells from affected family members, as were IL-5 protein levels in supernatants from both stimulated PBMC and ILC2 cultures.

conclusionsThese data are consistent with the hypothesis that the eosinophilia in FE is secondary to dysregulation of IL-5 production in PBMC (and their component subsets).

Indexed as

Cells, CulturedEosinophiliaGene ExpressionHumansInterleukin-5Leukocytes, MononuclearLymphocyte SubsetsReal-Time Polymerase Chain ReactionRNA, MessengerIL5 protein, humanInterleukin-5RNA, Messengerautosomal dominantcytokineeosinophilhypereosinophilic syndromeinterleukin 5

Identifiers

PMID28226398
PMCPMC5546948
OpenAlexW2589903290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.